BofA lowered the firm’s price target on Cronos Group (CRON) to $1.65 from $2 and keeps an Underperform rating on the shares. On April 3, the White House laid out its Drug Policy priorities for the first year of President Trump’s term and cannabis rescheduling that was started under President Biden was not part of the list, the analyst noted. The firm believes Cronos’ valuation will remain pressured given “continued unfavorable industry news and market conditions,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRON:
- Cronos Group Appoints Anna Shlimak as New CFO
- Cronos Group appoints Shlimak as Chief Financial Officer
- Largest borrow rate increases among liquid names
- Cronos Group’s Growth Hindered by Capacity Constraints and Market Limitations, Maintains Sell Rating
- Cronos Group Reports Strong 2024 Financial Results